Jordi Remon, Thoracic oncologist at CIOCC Barcelona, shared on X:
“TelisoV+Osi potential ttx in MET overex meta EGFRm NSCLC with osi resist disease.
Hw:
Other ADCs with activity
Not easy tissue Bx at PD for testing MET
New 1stL options may decrease MET expression at PD?
Brain activity.”
Teliso-V and osimertinib: the METamorphosis of EGFR-mutant lung cancer? – Annals of Oncology
Authors: S.P.L. Saw
